No Data
No Data
Bernstein Upgrades Beam Therapeutics(BEAM.US) to Buy Rating, Raises Target Price to $37
Beam Upgraded by Bernstein Ahead of AATD Data
Beam Therapeutics Price Target Raised to $37 From $35 at Bernstein
Express News | Beam Therapeutics Inc : Bernstein Raises to Outperform From Market Perform; Raises Target Price to $37 From $35
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now?
Cathie Wood's ARK Investment Buys 116K Shares of Beam Therapeutics Today